A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 23, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Autoimmune Hepatitis
Interventions
DRUG

zetomipzomib

Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly

DRUG

placebo

Subcutaneous injection of placebo

DRUG

zetomipzomib in open-label extension

Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly

Trial Locations (24)

10016

New York University Langone Health/Grossman School of Medicine, New York

11030

Northwell Health Center for Liver Disease and Transplantation, Manhasset

19104

University of Pennsylvania, Philadelphia

23298

Virginia Commonwealth University, Richmond

27710

Duke University Medical Center, Durham

32224

Mayo Clinic Florida, Jacksonville

33136

University of Miami, Miami

44106

University Hospitals Cleveland Medical Center, Cleveland

46202

Indiana University, Indianapolis

48109

University of Michigan Medical Center, Ann Arbor

60611

Northwestern University, Chicago

60612

Rush University, Chicago

63110

Washington University School of Medicine, St Louis

70121

Ochsner Clinic Foundation, New Orleans

80045

University of Colorado, Aurora

85054

Mayo Clinic Arizona, Phoenix

90033

Keck School of Medicine of USC, Los Angeles

90095

University of California, Los Angeles, Los Angeles

94063

Stanford Medicine, Redwood City

94109

California Pacific Medical Center, San Francisco

94132

University of California, San Francisco, San Francisco

06510

Yale University, New Haven

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Kezar Life Sciences, Inc.

INDUSTRY

NCT05569759 - A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) | Biotech Hunter | Biotech Hunter